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ABSTRACT
Objectives: To identify factors associated with the
decisions of the Federal Department of Home Affairs
concerning coverage with evidence development (CED)
for contested novel medical technologies in
Switzerland.
Design: Quantitative, retrospective, descriptive
analysis of publicly available material and prospective,
structured, qualitative interviews with key stakeholders.
Setting: All 152 controversial medical services
decided on by the Federal Commission on Health
Insurance Benefits within the framework of the new
federal law on health insurance in Switzerland from
1997 to 2013, with focus on 33 technologies assigned
initially to CED and 33 to evidence development
without coverage.
Main outcome measures: Factors associated with
numbers and type of contested services assigned to
CED per year, the duration and final outcome of the
evaluations and perceptions of key stakeholders.
Results: The rate of CED decisions (82 total; median
1.5/year; range 0–9/year), the time to final decision
(4.5 years median; 0.75 to +11 years) and the
probability of a final ‘yes’ varied over time. In logistic
regression models, the change of office of the
commission provided the best explanation for the
observed outcomes. Good intentions but absence of
scientific criteria for decisions were reported as major
comments by the stakeholders.
Conclusions: The introduction of CED enabled access
to some promising technologies early in their life
cycle, and might have triggered establishment of
registries and research. Impact on patients’ outcome
and costs remain unknown. The primary association of
institutional changes with measured end points
illustrates the need for evaluation of the current health
technology assessment (HTA) system.
INTRODUCTION
Health technology assessment (HTA) is con-
sidered essential in any solidarity-based
healthcare system for supporting funding
decisions. The rising gap between unlimited
requests and limited resources requires trans-
parent assessment of allocation of funds.
Traditionally, HTA has used the instruments
of evidence-based medicine such as a system-
atic search of high-quality research. The
rapid development of novel medical services
(including drugs, devices, diagnostics and
interventional procedures) increasingly
requires funding decisions before sufﬁcient
evidence has been generated.1 On the one
hand, there is a desire not to commit to a
technology that may ultimately prove to be
ineffective and/or unsafe. On the other
hand, there is a wish to provide patient
access to promising innovative approaches
early in their life cycle. For such situations,
in many jurisdictions around the world,
funding has been linked with the require-
ment of further evidence development typic-
ally with the help of a registry or a clinical
Strengths and limitations of this study
▪ Comprehensive analysis of all medical technolo-
gies submitted to ‘Coverage with Evidence
Development’ (CED) within one country over a
defined time frame.
▪ Additional structured qualitative interviews with
the key stakeholders in the process in order to
understand the mechanisms associated with the
decision process and changes over time.
▪ The finding that institutional changes provided
the best explanation for an association with the
many major changes in the process in logistic
regression models underlines the need for scien-
tific analyses of CED as a valuable tool in health
technology assessment (HTA).
▪ The retrospective nature of the study and the
absence of data on patients’ outcome and costs
limit assessment of the real value of CED.
▪ It might be difficult to generalise the results to
countries with other healthcare systems.
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trial. Different terms have been used, the most promin-
ent being ‘Coverage with Evidence Development’
(CED), deﬁned as a type of managed entry agreement
between manufacturers or service providers and the
paying healthcare system.2–7 Despite its many deﬁcien-
cies and its dependency on political decisions, CED has
been considered by many to be the tool to evaluate evolv-
ing technologies, but the best approach remains
unknown.8–10
Switzerland has used the CED concept for non-drug
technologies since 1996, when the new Federal Law on
Basic Health Insurance (KVG/LAMal) came into force.
With this new law, it became mandatory for each resi-
dent in the country to buy a basic health insurance
package from one of about 60–70 competing health
insurance companies. The law stipulates that individual
medical technologies have to be covered when they are
considered ‘effective’, ‘appropriate’ and ‘efﬁcient’.
These three terms are central in Swiss legislation and
are preconditions for coverage by the Swiss statutory
health insurance scheme. In the case of medical services
(including in vivo diagnostics and devices but not drugs
and not in vitro diagnostics) provided by physicians or
hospitals, it is assumed that these criteria are fulﬁlled by
default and no formalised HTA process is necessary for
reimbursement. This is called the ‘principle of trust’. In
case of doubt, however, anyone with a legitimate interest,
for example, a health insurance provider, can challenge
the medical service and a formalised HTA process is trig-
gered.11 Such a potentially controversial medical service
has to be reported to the Federal Ofﬁce of Public
Health (FOPH), which is responsible for, among other
things, the supervision of the health beneﬁt catalogue.
The provider or the manufacturer has then to submit
full documentation of the available evidence on effect-
iveness (including a systematic review), appropriateness
and cost-effectiveness. The FOPH checks the submission
for completeness and writes a summary including crit-
ical issues. All information on the case is assembled in a
dossier which is handed over to the Federal Commission
for Medical Beneﬁts and Principles (ELGK) for
appraisal. The ﬁnal decision lies with the Federal
Department of Home Affairs (EDI), the parent organisa-
tional unit of the FOPH, and it is published in the pro-
cedures ordinance (KLV/OPAS) related to the health
insurance law.
Since its introduction on 1 January 1996 the possible
decision was not limited to ‘yes’ and ‘no’ but also ‘yes,
in evaluation’ for novel and promising medical tech-
nologies where the existing evidence was incomplete.
Under this status, the medical service was reimbursed
but with the stated goal of further evidence collection.
This status comes with an initial period of time which is
frequently extended if the evidence is still incomplete.
Hence, CED had been used in Switzerland for many
years without being formally labelled as such.
Finally, before 2004 a number of services were listed as
‘no, in evaluation’ in the procedures ordinance. Those
services could be provided. However, they were not reim-
bursed by the health insurance scheme and had to be
ﬁnanced by other means, for example, a research grant
or private insurance. Therefore, they cannot be labelled
CED. However, they could be upgraded to ‘yes’ or ‘yes,
in evaluation’ later in the process. The decision option
‘no, in evaluation’ was abandoned in 2004 since it did
not have any practical signiﬁcance from a governance
perspective.
A recent descriptive analysis provided some insight
into incidence, duration and ﬁnal outcome of the CED
decisions in Switzerland. No structured evaluation was
made; no factors associated with decisions or outcome
were looked for.12 There is increasing awareness of a
need for decisions based on HTA, a rising concern
about ‘the second gap’ in translation (the ‘ﬁrst gap’
exists in the translation of knowledge from benchmark
to new medical interventions, and the ‘second gap’ from
new medical interventions to clinical application), but
little information on evaluation of HTA decisions in the
literature in general.13 14 We aimed to learn more about
the relative frequency of CED decisions compared to the
total number of decisions on contested medical services
and on potential factors associated with the ﬁnal reim-
bursement decision.
METHODS
Study design
A mixed-methods approach was used. In a longitudinal
retrospective quantitative analysis of publicly available
data we searched for factors associated with initiation,
duration and outcome of CED decisions; with focused
qualitative interviews of key stakeholders we searched for
soft factors within the multilevel decision process.
No individual patient data were analysed; no ethics
committee approval was required.
Data collection
The study followed the principle of a previous analysis
but looked at all 152 initial decisions by the Federal
Department of Home Affairs (EDI/DFI) regarding con-
tested medical services since 1996 (ﬁgure 1). The deci-
sions are published in online supplementary annex 1 of
the procedures ordinance to the law on Health
Insurance (KLV/OPAS) which is updated at least once a
year and is publicly available on the webpage of the
FOPH (http://www.bag.ch). All decisions on new proce-
dures year after year from 1996 until 2013 were looked
up manually by the research team. All decisions with a
formal ‘yes, in evaluation’ or ‘no, in evaluation’ were
selected for detailed analysis. Information on decision,
duration of CED state, restrictions and requirements was
extracted.
Information on the number of decisions per year that
directly lead to a ‘yes’ or ‘no’ was provided by the FOPH
along with additional information on the sequence of
decisions on reimbursement, as illustrated in ﬁgure 1.
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Decisions with a formal ‘yes’, but an additional
requirement for, for example, a registry or reanalysis
after a speciﬁed time interval were not included, despite
their ‘conditional’ strings. All contested medical services
were grouped by their type of technology as deﬁned by
the EuroScan database (http://euroscan.org.uk/) into
diagnostics, procedures, devices and programmes.15
Analysis concentrated on factors associated with inci-
dence, duration and outcome of the process (see online
supplementary tables S1).
Factors analysed for an association with the CED process
We analysed the association of restrictions and require-
ments imposed on the evaluations with the ﬁnal reim-
bursement decision and the duration of the evaluation.
Explanatory variables encompass restrictions to speciﬁed
centres or specialists, previous approval by a medical
advisor of the health insurer or the requirement for a
registry. No public information was available to us con-
cerning the submitter, the amount and quality of avail-
able evidence on efﬁcacy, safety and cost impact at the
time of the decision, burden of disease or unmet needs.
The association of institutional factors with the inci-
dence and the ﬁnal reimbursement decision was also
analysed. As factors reﬂecting the institutional environ-
ment, we considered the inﬂuence of the president of
the appraisal committee, the Federal Commission for
Medical Services and Policy Issues (ELGK/CFPP), and
the decisionmaker, the federal councillor of the Federal
Department of Home Affairs.
The president of the appraisal committee has agenda
setting power and is therefore the most important
member of the ELGK. The federal councillor in charge
is the ﬁnal decisionmaker. He or she is in the role of the
health minister although formally Switzerland does not
have one. His or her decisions are based on, but are
independent from, the recommendation by the ELGK.
Most decisions however follow the recommendations by
the commission. A further important institutional factor
could have been the federal ofﬁce that the ELGK was
assigned to. While originally it belonged to the federal
social insurance ofﬁce, it became part of the FOPH
in 2004.
Structured qualitative interviews
Focused interviews following Merton and Kendell16 were
conducted with past and current members of the
appraisal committee (ELGK/CFPP) and representatives
of the FOPH who also chaired the committee until
2011, when this was changed for governance reasons.
The selection of the interviewees was carried out by way
of theoretical sampling in order to represent as many
different perspectives as possible.17 Ten interviews were
conducted with 11 people because one interview was
carried out with two people. Seven interviewees were
members of the appraisal committee (current members:
4; past members: 3). Three of the interviewees were
current or former presidents of the committee. Five of
the interviewed committee members were representing
a stakeholder group (health insurers: 2; service provi-
ders: 2; patients: 1). Five interviewees were representing
the FOPH and included both current and past
members. Eight interviewees were medical doctors by
training whereas four were lawyers (one had a double
degree). Individuals can have multiple characteristics.
The focused interviews were designed to validate the
results generated in the statistical analysis, to ease inter-
pretation of the results, to better understand the context
and the nature of the decision-making process, to shed
light on the decision-making dynamics hidden in the
‘black box’, and to learn about different individual per-
spectives and interpretations of the situations by the
experts. The interviews were based on a semistructured
questionnaire (see online supplementary material); they
were all carried out face-to-face, they lasted between 50
and 120 min and they were audio taped and transcribed
before analysis. The analysis was performed by iterative
reading by one author (UB) and free codes were
applied. Statements on the same emerging themes were
grouped in tabulated form. A second author (AG) read
all the interviews and crosschecked the results.
Statistical data analysis
Factors associated with the incidence of new evaluations
and with the ﬁnal decision, respectively, were identiﬁed
using logistic regression. We tested the inﬂuence of the
explanatory variables by means of deviance tests.
Variable selection was based on Akaike’s Information
Criterion (AIC).18 19 Time to event was evaluated using
cumulative incidence functions estimated by a propor-
tional cause-speciﬁc hazard model.20 All analyses were
conducted in R 3.0.2.21
For the detailed analysis, we excluded technologies of
alternative medicine (such as homeopathy, acupuncture,
anthroposophical medicine, traditional Chinese medi-
cine or phytotherapy) due to the strongly political
nature of decisions in this ﬁeld. In a referendum, the
Swiss population decided in May 2009 to keep
Figure 1 Multistate Model of 152 contested medical
technologies decided on by the Federal Commission on
Health Insurance Benefits in Switzerland from 1996 to 2012.
The figure depicts the transitions from one evaluation state to
another to a final ‘yes’ or final ‘no’.
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alternative medicine within the mandatory health insur-
ance scheme. The approval rate was 67%.
RESULTS
Use of ‘CED’ in Switzerland from 1996 to 2012
We distinguish between two related concepts. First, we
consider the number of medical services evaluated.
Second, we evaluate the number of decisions on the
reimbursement of these services. Medical services that go
through a period of CED change their state at least twice,
some even more often. Consequently, two or more deci-
sions are made until a ﬁnal reimbursement decision has
been reached. Over time, a total of 152 contested
medical services were evaluated and 234 decisions were
made by the commission (ﬁgure 1). For 86 (57%) of the
medical services, a direct decision for acceptance (N=50;
33%) or rejection (N=36; 24%) was made. No further
details were collected on these decisions. For 66 services
(43%), the requirement ‘in evaluation’ was added by the
commission at their ﬁrst decision, for 33 each as ‘yes, in
evaluation’ or ‘no, in evaluation’ (ﬁgure 1).
‘In evaluation’ was added in total for 82 (35%) of the
234 decisions (table 1). Of these, 46 medical services
(20%) were assigned with ‘yes, in evaluation’ and conse-
quently became CED (ﬁgure 2A). They concerned all
types of contested services: alternative medicine proce-
dures (N=10; 22%; concerning 5 services, all evaluated
twice), therapeutic procedures (N=24; 52%), diagnostics
(N=8; 17%), medical devices (N=8; 17%) and pro-
grammes (N=3; 7%). The frequency of these different
types varied over time. In the beginning many services
were diagnostics, while in more recent years there were
none. Evaluation of programmes in turn was only taken
up in more recent years (see ﬁgure 2A). Slightly fewer
decisions were designated with ‘no, in evaluation’ (36 of
234; 15%; ﬁgure 2B).They concerned primarily thera-
peutic procedures (N=24; 67%), with a few diagnostics
(N=4; 11%), medical devices (N=7; 19%) and pro-
grammes (N=1; 3%).
For the majority of the initial ‘yes, in evaluation’ deci-
sions, CED was linked with one or more additional
requirements. The procedure was either restricted to a
specialist physician (N=18; 39%), or a specialised centre
(N=20; 43%) or required a registry (N=14; 30%).
Similarly, some ‘no, in evaluation’ decisions were
restricted to a specialised centre (N=3, 8%) or to the
requirement for a registry (N=3, 8%; see online supple-
mentary tables S1a–c). Decisions may impose multiple
restrictions and often do so, as can be seen from table 1.
The number of restrictions imposed clearly exceeds the
number of decisions made.
Factors associated with initial decisions
The number of annual initial decisions by the commis-
sion changed signiﬁcantly over time and ranged from 3
to 28 (ﬁgure 3). The number of initial decisions on new
services to proceed with ‘yes, in evaluation’ ranged from
0 (1997, 2003, 2004, 2008, 2010, 2011) to 6 (2002) with
an average of 2.6 per year. New decisions for ‘no, in
evaluation’ were only made from 1996 to 2004; they
ranged from 1 (1996–1999) to 17 (2002) per year with
an average of 3.4 per year during these 9 years. There is
a noticeable difference in new ‘CED’ decisions by the
commission before and after 2005 with a mean number
of new decisions of 3 (2.44, when alternative medicine is
excluded) before, 1.78 (1.22, when alternative medicine
is excluded) after 2005. However, these differences were
statistically signiﬁcant only at a 10% level (p=<0.1; with
and without alternative medicine).
We found no association between the share of deci-
sions for CED and the organisational unit of the com-
mission, the president of the commission or the federal
councillor.
Outcome of ‘CED’ evaluation
A decision was made for 37 out of 46 ‘yes, in evaluation’
cases (80%) and for 35 out of the 36 ‘no, in evaluation’
cases (97.2%) by the end of 2013. Final reimbursement
(‘yes’) was granted in 59.4% and 42.9% of all decisions
respectively. The average duration of the evaluation was
a total of 5.36 years (4.3 years initial and +1.07 years
extension) for the 37 ‘yes, in evaluation’ cases that were
already decided with a high variation (0.5–11 years) and
most decisions (23 out of 37; 62.2%) were made
Table 1 Numbers of CED decisions in Switzerland from 1996 to 2012 by type of medical technology* and additional
requirements†
Technology
‘Yes, in evaluation’ ‘No, in evaluation’
TotalTotal
Thereof with restriction of
Total
Thereof with restriction of
Centre Specialist Registry Centre Specialist Registry
Diagnostics 8 4 4 6 7 15
Devices 10 7 1 4 14
Procedures 25 8 13 7 24 3 3 49
Programmes 3 1 1 1 4
Total 46 20 18 14 36 3 0 3 82
*According to EuroScan database.9
†Restriction to certain specialists, centres, devices, or linked with the requirement for a registry.
CED, coverage with evidence development.
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Figure 2 (A) Sequence of decisions by the commission by type of technology. Depiction of the 46 coverage with evidence
development ‘CED’ decisions ‘yes, in evaluation’. Colours are according to the type of medical technology as defined by
EuroScan15(devices (grey), diagnostics (orange), procedures (blue) and programmes (green)). Bars represent time from initial
decision to final decision. Intercepts indicate prolongation of the initial evaluation period. Symbols to the right of bars show the
decision that ended the evaluation period. (B) Sequence of decisions by the commission by type of technology. Depiction of the
36 ‘CED’ decisions ‘no, in evaluation’. Colours are according to the type of medical technology as defined by
EuroScan15(devices (grey), diagnostics (orange), procedures (blue) and programmes (green)). Bars represent time from initial
decision to final decision. Symbols to the right of bars show the decision that ended the evaluation period.
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between 5 and 8 years after initiation of the evaluation.
The respective duration of the evaluation was 7.25 years
for the 35 ‘no, in evaluation’ cases with again a high
variation (0.5–21 years).
Most potential paths in the multistate model occurred,
the exceptions being transitions from ‘yes’ to ‘no’ or
‘no, in evaluation’ and from ‘no’ to ‘no, in evaluation’
(ﬁgure 1).
Factors associated with final decisions
Looking at all evaluations classiﬁed as ‘yes, in evaluation’
that had already arrived at a ﬁnal decision, no associ-
ation was found between ﬁnal outcome and require-
ments and restrictions, such as restriction to specialist
physician, restriction to specialised centres or conduct of
a registry. In contrast, the probability of a positive ﬁnal
decision changed signiﬁcantly when the ELGK became
associated with the FOPH (p<0.01), when the heads of
the Federal Department of Home Affairs (p<0.05) were
replaced and when the concurrent chair of the appraisal
committee (ELGK/CFPP) changed (p<0.05). The
strong correlation between these three factors does not
permit identiﬁcation of a unique source of this variation.
However, according to the AIC, the association with the
FOPH provides the most parsimonious model that ﬁts
the data well.
Analysing the association of restrictions and require-
ments with time until decision, we found that duration
was signiﬁcantly longer when any restriction or require-
ments did apply (p<0.01). This ﬁnding should not be
necessarily interpreted in a causal way, since it may just
indicate that more difﬁcult cases were accompanied by
technical requirements.
Registries
For a total of 14 (30.4%) cases classiﬁed as ‘yes, in evalu-
ation’ conduct of a registry was required. No criteria
were speciﬁed on how and by whom the registry had to
be established or how the registry was ﬁnanced. No
public data of any of the registries is available.
There is one exception. ‘CED’ for certain haematopoi-
etic stem cell transplants was linked with the require-
ment for ‘JACIE’ accreditation of the transplant centre
as a prerequisite for reimbursement.22 Adherence to the
‘JACIE’ quality management system ( Joint Accreditation
Committee of the International Society for Cellular
Therapy and the European Group for Blood and
Marrow Transplantation; http://www.jacie.org) implies
reporting of all haematopoietic stem cell transplants,
those on ‘CED’ as well as all other indications, to the
Swiss and the European data registry.
Qualitative interviews
The standardised qualitative interviews with key experts
and past and present committee members identiﬁed
several highly consistent ﬁndings. All participants
believed in the value of CED, were convinced that this
strategy did provide early access to promising therapies
before ﬁnal evidence was established, and did take their
task seriously. They noted that the appraisal committee
should give a recommendation but at the same time
provide neutral expertise. The appraisal committee
Figure 3 Numbers of new evaluations 1996 to 2013. Number of total new evaluations and number of new coverage with
evidence development evaluations. Vertical lines show changes in the institutional environment, either a new office (green dotted
line), a new president (red solid lines) or a new federal councillor (blue dotted lines).
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faced the challenge of considering efﬁcacy and cost-
effectiveness while the pricing for a medical service was
decided on elsewhere. The interviewed realised that the
durations between the evidence generation and the ﬁnal
decision-making varied considerably and were sometimes
too long. They recognised the enormous workload
Table 2 Contradictory elements as emerging themes in the CED process in Switzerland
Positive elements Negative elements
Key problems ▸ Office can/must decide
▸ ‘WZW’ at center of decision-making
▸ CED integrates HTA (evidence generation)
and decision-making
▸ Should provide expertise but remain neutral
▸ Pricing (in Switzerland) independent from
evaluation
▸ Time frame varies too much
The role of rules ▸ Safeguard against arbitrariness and randomness
▸ Guarantees accountability and reasonableness
(clear processes as eg, NICE in England has it)
▸ Random variations over time are reality
▸ Rigid process blocks flexibility; pragmatic and
potentially very efficient decisions in
individual situation not possible
Transparency vs
confidentiality
▸ Transparency essential for fair process,
reasonableness and accountability
▸ Confidentiality permits members to be honest
and open during the meeting
▸ Transparency induces public pressure on
committee members and lobbying
▸ Transparency can violate the interests of
manufacturers
▸ Confidential information cannot be used for
other purposes, for example, economic
assessment, price negotiations.
▸ Confidentiality carries risk of inefficiency
Efficiency and
resources
▸ Commissioners are devoted to task
▸ Swiss process is lean and efficient
▸ Risk of work overload for committee
members through time constraints, poor
preparation of meetings, broad range of
topics and language barriers
▸ Not all technologies get the same attention
▸ Decision can be arbitrary
Political pressure ▸ Department in principle follows recommendation
of commission
▸ Pressure on commissioners less severe than
in drug commission (no individual products;
rather class products)
▸ Pressure by pressure groups, med tech
industry, media
CED as a struggle ▸ CED for controversial medical technologies is
part of the reimbursement decision-making
process and should improve ‘WZW’
▸ Different interests are represented in commission
▸ Commission and FOH realise key deficiencies in
process
▸ Evidence frequently not better after CED
phase but difficult to say ‘no’ at the end of a
CED process.
▸ No rules yet in Swiss CED process: (a) when
to use CED; (b) how to define and what
methodology to use for open questions; (c)
how to guarantee the quality of the evaluation
(compliance of service providers, financing)
▸ Bad compromises, not necessarily the most
competent experts are chosen
▸ Time constraints, Transparency, Resources,
Process definition, Feedback to the
commission (evaluation of the evaluation)
Changes over time ▸ Decisions more based on evidence, more
scientific
▸ More realistic perception of CED (and its
possibilities and limits)
▸ More diverse commission
▸ More cases, more documents, more work
(over)load,
▸ High turnover of people at BAG (loss of
knowledge)
▸ More heterogeneous commission
Different interests
need to be balanced
▸ Patients demand access
▸ Physicians want to use novel, promising therapies
▸ Industries (researchers) want to sell products
▸ Payers need to control costs
▸ Federal office follows laws
▸ Commissioners strive for correct decisions
Based on qualitative structured interviews (for details see methods).
CED, coverage with evidence development; FOH, Federal Office of Public Health; HTA, health technology assessment; NICE, National
Institute for Health and Care Excellence; WZW, decision criteria (effectiveness, appropriateness and cost-effectiveness).
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associated with the documentation and the impossibility
for each member of the commission to judge details.
They considered the criteria to become listed as a con-
tested medical procedure in part erratic, dependent on
the presiding chair, the composition of the committee,
and the documentation by the applicants.
They mentioned the lack of criteria to arrive at a ‘yes’,
a ‘yes, in evaluation’, a ‘no, in evaluation’ or a ‘no’ and
the lack of standardised criteria on when to link a deci-
sion with additional requirements, such as restriction to
speciﬁed providers or the conduct of a registry. They
noted the major, in part divergent conﬂicts of interest
but all agreed on the need for an evaluation of the
evaluation (table 2).
DISCUSSION
This comprehensive overview on the use of CED in one
country over nearly two decades illustrates a major chal-
lenge to HTA: institutional factors dominated the use of
CED and ﬁnal decisions. Granting access to novel but
contested medical procedures via CED in Switzerland
varied signiﬁcantly over time; so did the result of ﬁnal
decisions. The factors identiﬁed as signiﬁcantly asso-
ciated with input to and output from the system were
the organisational units of the commission, the heads of
the Federal Department of Home Affairs and the con-
current head of the appraisal committee (ELGK/CFPP).
The strong correlation between these three precluded
further identiﬁcation; still, change of the department
did provide the most plausible explanation.
The role of politics in the decision-making process is
not necessarily bad in a democratic country but it is a
fact that should be recognised. There is little scientiﬁc
research on this aspect, an exception being a recent
qualitative analysis of expert interviews.9 The Swiss popu-
lation demanded re-access in a referendum when alter-
native medicine failed to stand the test of evidence and
was waived from the list of standard insurance beneﬁts.23
In any solidarity-based or democracy-based Health Care
System, participants should have the right to express
their values. However, assessment and appraisal should
be clearly separated.24
The absence of clear criteria for a CED decision and a
deﬁnition of the decision pathway, the arbitrariness in
decision-making, and the lack of scientiﬁc evaluation of
what was performed were key comments from the inter-
views. In the related ordinance (KLV/OPAS), deﬁnitions
varied, sometimes from one edition to the next.
Additional requirements such as conduct of a registry or
limitation to deﬁned centres or specialists followed in
part erratic patterns, despite the establishment of a
series of handbooks for the commission. Impact of these
instructions could not be assessed in this study. The spe-
ciﬁc label ‘no, in evaluation’ was abandoned without
evaluation in 2004. It was considered to have no
practical meaning, since providers or producers of any
medical service had the possibility to resubmit a ﬁle as
soon as new evidence was generated. Of note in this
context, the initial decision ‘no, in evaluation’ for
autologous haematopoietic stem cell transplantationin
autoimmune disorders was crucial to obtaining research
funds and did stimulate initiation of a multicenter pro-
spective randomised study with an ultimately successful
outcome.25–28
Similarly, the use of registry was required in 14 cases;
no speciﬁc recommendations or support structures were
linked to these requests. Unsurprisingly, information on
status of registries was minimal at best, with few excep-
tions. With the introduction of a Swiss law on transplant-
ation, reporting of all transplants to the Swiss registry
and adherence to the quality management system
‘JACIE’ became mandatory in Switzerland in order to be
reimbursed. Reporting was reimbursed as well.29 Hence,
haematopoietic stem cell transplantation in Switzerland
presents a successful model with comprehensive report-
ing and documented improvement in outcome.22
Changes from CED to acceptance (eg, multiple
myeloma, autoimmune disorders) or rejection (eg, lung
cancer or melanoma) were based on national and inter-
national scientiﬁc criteria. As a tool, CED could speciﬁc-
ally apply to the emerging diagnostic and therapeutic
services of personalised medicine, where standard phase
III trials no longer sufﬁce.30
The qualitative data of the structured interviews sup-
ported the quantitative ﬁndings. All persons asked con-
ﬁrmed the seriousness of the participants, the
willingness ‘to do their best’ but were concerned about
the erratic structure of the evaluation process. They felt
informed about CED as an evaluation tool and strongly
believed in the concept. They were convinced that CED
did indeed permit early access to novel therapies for
patients in need and generate new evidence. They
expressed their concern about the lack of scientiﬁc and
administrative criteria and the absence of evaluation of
the evaluation process itself. They criticised in part the
absence of academia from the HTA appraisal process.
A review of the literature reveals that less than 10% of all
the publications which were searched for the term
‘CED’ appear in general medicine journals, a minute
amount in high-ranking medical journals.31 32 This lack
of interest is historical and can vary between benign
neglect and interest-driven aversion by the medical pro-
fession.33 In the Swiss context, no medical faculty in
Switzerland holds a chair on HTA. This lack of interest
of academia in HTA has recently been discussed.28
This report has limitations and weaknesses. We con-
centrated on publicly available material, for example,
the KLV ofﬁcial publications. The inconsistency in these
reports precludes an unbiased analysis. Some medical
services were listed in a different format from year to
year. For the sake of the analysis we deﬁned them as
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presented. We did not evaluate the decisions with a
direct ‘yes’ or ‘no’. We could not evaluate the potential
impact of the internal learning process of the commis-
sion, of the related structural changes, or of changes in
the Swiss Health Care System in general. The commis-
sion and related structures are in a constant learning
process, which is highlighted by background documents
available on the website of the FOPH. The setup of HTA
and decision-making was audited by the parliament in
2008/2009 and is due to be developed further with the
plans of the government to establish permanent struc-
tures for HTA and quality which at present are under
public consultation. Still, some clear ﬁndings can be
described and are useful when developing structures
and processes further.
CONCLUSION
This analysis of 17 years of CED in Switzerland describes
its potential beneﬁts and deﬁciencies. The introduction of
CED enabled access to some promising technologies early
in their life cycle, and might have triggered the establish-
ment of registries and research. Impact on patients’
outcome and costs remains unknown. Furthermore, CED
increases the complexity of the decision-making process;
CED recommendations should be made with care. They
should follow internationally agreed principles8 and be
integrated into a clear and structured process and consist-
ent decisions. The primary association of institutional
changes with measured end points illustrates the need for
evaluation of the current HTA system.
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